Cargando…

Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure

Effectiveness of therapy with individual disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is limited, and the number of available DMARDs is finite. Therefore, at some stage during the lengthy course of RA, institution of traditional DMARDs that have previously been applied...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapral, Theresa, Stamm, Tanja, Machold, Klaus P, Montag, Karin, Smolen, Josef S, Aletaha, Daniel
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526609/ https://www.ncbi.nlm.nih.gov/pubmed/16507172 http://dx.doi.org/10.1186/ar1902

Ejemplares similares

Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
por: Kapral, Theresa, et al.
Publicado: (2007)

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
por: Aletaha, Daniel, et al.
Publicado: (2005)

Value of self-performed joint counts in rheumatoid arthritis patients near remission
por: Radner, Helga, et al.
Publicado: (2012)

Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?
por: Machold, Klaus P, et al.
Publicado: (2006)

Developments in the clinical understanding of rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2009)

Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis
por: Mandl, Peter, et al.
Publicado: (2020)

Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort
por: Biliavska, Iuliia, et al.
Publicado: (2013)

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
por: Studenic, Paul, et al.
Publicado: (2023)

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision
por: Studenic, Paul, et al.
Publicado: (2022)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
por: Aletaha, Daniel, et al.
Publicado: (2015)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
por: Stamm, Tanja Alexandra, et al.
Publicado: (2018)

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
por: Gärtner, M, et al.
Publicado: (2016)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
por: Radner, Helga, et al.
Publicado: (2014)

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
por: Smolen, Josef S, et al.
Publicado: (2018)

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
por: Radner, Helga, et al.
Publicado: (2015)

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
por: Smolen, Josef S, et al.
Publicado: (2011)

Effects of a brief workplace-centered consultation for employees with musculoskeletal pain on health outcomes: a prospective cohort study
por: Leiss, Harald, et al.
Publicado: (2019)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
por: Smolen, Josef S, et al.
Publicado: (2008)

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns
por: Platzer, Alexander, et al.
Publicado: (2019)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Autoantibodies in very early rheumatoid arthritis: diagnostic tools or pathogenic players?
por: Steiner, G, et al.
Publicado: (2003)

Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature
por: Karonitsch, Thomas, et al.
Publicado: (2022)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

The diagnostic significance of autoantibodies in patients with very early rheumatoid arthritis
por: Nell, V, et al.
Publicado: (2003)

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
por: Smolen, Josef S., et al.
Publicado: (2018)

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials
por: Smolen, Josef, et al.
Publicado: (2019)

A Plea for More Frequent Employment
Publicado: (1919)

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
por: Salem, Heba F., et al.
Publicado: (2022)

The science of rheumatoid arthritis: a prelude
por: Smolen, Josef S
Publicado: (2005)

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
por: Schoels, M., et al.
Publicado: (2017)

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2019)

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor
por: Tan, Eng M., et al.
Publicado: (2016)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Autoantibodies in rheumatoid arthritis and their clinical significance
por: Steiner, Günter, et al.
Publicado: (2002)

Patient education, disease activity and physical function: can we be more targeted? A cross sectional study among people with rheumatoid arthritis, psoriatic arthritis and hand osteoarthritis
por: Drăgoi, Răzvan G, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_eoptdmrqcpu314cfdpp1nqqgq5